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Prednisolone and adrenocorticotropic hormone (ACTH) are “hormone” therapies for 
infantile spasms. There is limited data on the occurrence of decreased adrenal reserve 
or signs of clinical adrenal insufficiency after hormone therapy. This is a retrospective 
medical record review of patients referred to our Infantile Spasms Program. Our stan-
dardized infantile spasms management guideline began in September 2012 and initially 
included a post-hormone laboratory assessment of adrenal function. Medical records 
were assessed for hormone treatments, adrenal function testing, and signs of adrenal 
insufficiency. Forty-two patients who received one or both hormone therapies met inclu-
sion criteria. A post-hormone laboratory assessment of adrenal function was done in 
14 patients. Of these 14 patients, 2 had an abnormal laboratory assessment of adrenal 
function, both by adrenal stimulation testing – one after ACTH and one after prednis-
olone. One patient received hydrocortisone replacement and the other received stress 
dose hydrocortisone as needed; neither patient developed signs of adrenal insufficiency. 
Another patient treated with both types of hormone therapy in tandem, who did not have a 
post-hormone laboratory assessment, developed signs of mild adrenal insufficiency and 
required replacement hydrocortisone. Our study suggests that adrenal suppression can 
occur after modern hormone therapy regimens. We found two patients with abnormal 
adrenal function testing after hormone therapy and another patient with signs adrenal 
insufficiency. Given the seriousness of adrenal crisis, caregiver education on the signs of 
adrenal insufficiency is critical. Greater vigilance may be indicated in patients receiving 
both types of hormone therapy in tandem. Although a routine post-hormone laboratory 
assessment of adrenal function may not be feasible in all patients, replacement or stress 
dose hydrocortisone is necessary for all patients with suspected adrenal insufficiency.
Keywords: infantile spasms, West syndrome, adrenal insufficiency, adrenal function, adrenal stimulation testing, 
cortisol, adrenocorticotropic hormone, prednisolone
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inTrODUcTiOn
Infantile spasms are seizures that most often begin in the first year 
of life. Early and successful treatment of infantile spasms and the 
associated epileptic encephalopathy can improve developmental 
and seizure outcomes (1, 2). Adrenocorticotropic hormone 
(ACTH) and oral corticosteroids (most commonly prednisolone) 
are types of “hormone” therapies that are commonly used first-line 
treatments for patients with infantile spasms (3). Some infantile 
spasms patients who do not respond to ACTH will respond to oral 
corticosteroids, and vice versa (4). Thus, some clinicians switch 
to the alternative hormone therapy after a patient fails to respond 
to the first hormone therapy. In the United States, the duration of 
hormone therapy with ACTH or prednisolone is about 1 month 
(3, 5–7). Dosing regimens vary, but clinicians in the United States 
often use “high-dose” hormone therapy (3). High-dose regimens 
typically begin with 150 IU/m2/day for natural gel ACTH (5) and 
40–60 mg/day for oral prednisolone (8).
The risk of secondary adrenal insufficiency due to the suppres-
sion of the hypothalamic–pituitary–adrenal (HPA) axis follow-
ing long-duration high-dose corticosteroids is well known (9). 
Suppression of the HPA axis may be partial or total, as a result of 
adrenal gland atrophy, with great individual variability (10). Even 
short-duration corticosteroid therapy (e.g., 10 days) can lead to 
the suppression of the HPA axis (11). When steroid therapy is 
withdrawn in patients with suppressed adrenal function, acute 
adrenal insufficiency or Addisonian crisis may occur, which is a 
serious and potentially life-threatening condition. Signs of mild 
adrenal insufficiency are non-specific, but can include nausea, 
tiredness, poor feeding, and lethargy in young children. Signs of 
severe acute adrenal insufficiency can include vomiting, diarrhea, 
fever or hypothermia, hypotension, hypoglycemia, shock, and 
coma. No study has assessed adrenal function or the incidence 
of clinical adrenal insufficiency following the treatment of infan-
tile spasms with modern regimens of high-dose corticosteroid 
therapy.
Impaired pituitary ACTH response has been shown in adults 
following exogenous ACTH administration (12). Exogenous 
ACTH stimulates the adrenal gland, resulting in hypercortisolism, 
as evidenced in ACTH-treated infants who develop Cushingoid 
appearance as a result of this effect. The mechanism of decreased 
pituitary reserve following exogenous ACTH therapy has been 
postulated to result from hypercortisolemia, which suppresses 
pituitary ACTH secretion; this causes rapid involution of the 
adrenal cortex after stopping ACTH treatment and reduced 
responsiveness to ACTH stimulation (13).
There is very limited data available on the risk of suppression 
of the HPA axis following modern regimens of ACTH therapy 
for infantile spasms. There have been three small infantile 
spasms studies totaling 24 patients treated with ACTH who 
had a post-treatment assessment of adrenal function (13–15). 
Several patients were reported to have decreased pituitary and/
or adrenal reserve after stopping ACTH therapy (13–15). In 
these three studies, adrenal function was assessed either soon 
after stopping ACTH or up to 2 weeks later; these studies did 
not assess the occurrence of clinical adrenal insufficiency in the 
months following treatment. Although two large series of infan-
tile spasms patients treated with synthetic or natural ACTH did 
not report any cases of clinical adrenal insufficiency following 
treatment with ACTH, these studies did not assess adrenal func-
tion (16, 17). It is important to note that symptoms of clinical 
adrenal insufficiency in patients with a suppressed HPA axis may 
not be clinically evident without stress (e.g., febrile illness). It is 
also unknown if the risk of adrenal insufficiency is increased, if 
the alternative hormone therapy is used after the first hormone 
therapy, either when one is used immediately after the other 
(i.e., in tandem) or following a brief hiatus between hormone 
therapies.
At Nationwide Children’s Hospital, we created and imple-
mented a standardized management guideline for infantile 
spasms in September 2012. Given the uncertainty of adrenal 
insufficiency following hormone therapy for infantile spasms, 
and a personal experience of clinical adrenal insufficiency follow-
ing corticosteroid therapy in a patient with infantile spasms (18), 
our guideline initially included a post-hormone endocrinologist-
guided laboratory evaluation of adrenal function. Here, we report 
our experience with monitoring of adrenal function following 
hormone therapy for infantile spasms as well as the occurrence 
of clinical adrenal insufficiency.
MaTerials anD MeThODs
subjects and Treatment Protocol
We carried out a retrospective medical record review of patients 
referred to the Infantile Spasms Program at Nationwide 
Children’s Hospital from September 2012 to July 2015. The medi-
cal records of patients were assessed for hormone treatments, 
adrenal function testing, and clinical signs of post-treatment 
adrenal insufficiency. The goal of this study was to determine 
the frequency of decreased adrenal reserve or signs of clinical 
adrenal insufficiency in infantile spasms patients treated with 
hormone therapy.
Our management guideline emphasizes the initial treatment 
with first-line therapies which at our program include ACTH, oral 
prednisolone, and vigabatrin. After physician-guided counseling, 
caregivers and clinicians work together to choose the desired 
treatment. Given that some patients who fail to respond to ACTH 
will respond to oral corticosteroids, and vice  versa (4), some 
patients in this study received the alternative hormone therapy 
immediately after the first hormone therapy was deemed inef-
fective. Some patients received vigabatrin in between hormone 
therapies depending on the preferences for treatment. During the 
study period, natural gel ACTH was given at a dose of 75 IU/m2 
twice daily for 2 weeks followed by a taper over 15 days [30 IU/m2/
day for 3 days, 15 IU/m2/day for 3 days, 10 IU/m2/day for 3 days, 
and then 10 IU/m2/day every other day for three doses (5)] and 
prednisolone was given at a dose of 40–60  mg/day in three to 
four divided doses for 2 weeks followed by a 15-day taper [10 mg 
three times daily (or 10 mg four times daily for those that required 
a dose increase to 60 mg/day) for 5 days, 10 mg twice daily for 
5 days, and then 10 mg daily for 5 days (8)].
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assessment of the  
hypothalamic–Pituitary–adrenal axis
From September 2012 to July 2014, our infantile spasms man-
agement guideline included a recommendation for an endocri-
nologist-guided laboratory assessment of adrenal function after 
completion of hormone therapy. Given the relatively low yield of 
this testing and the lack of clinical signs of adrenal insufficiency 
with laboratory testing in 14 patients, we subsequently discon-
tinued these evaluations and instead relied upon clinical signs of 
adrenal insufficiency.
A laboratory assessment of adrenal function included an a.m. 
cortisol level and/or an assessment of adrenal function by glucagon 
stimulation test or ACTH stimulation test. Normal 8 a.m. cortisol 
is 3–21 μg/dl. The ACTH stimulation test was chosen more fre-
quently than the glucagon stimulation test given that the former is 
of shorter duration. For both tests, a fasting state is not required. 
Baseline serum cortisol levels (as well as serum ACTH levels for 
most patients) were drawn upon placement of a peripheral indwell-
ing intravenous line, which were then maintained by means of a 
heparin-lock needle. For glucagon stimulation testing, glucagon 
(Glucagen-Bedford Laboratories) at 0.03 mg/kg (maximum 1 mg) 
was given subcutaneously. Blood samples for serum glucose and 
cortisol were obtained at 60, 90, 120, and 150 min after glucagon 
administration. For ACTH stimulation testing, 1 μg of cosyntro-
pin (ACTH-[1-24], Cortrosyn-Amphastar Pharmaceuticals) was 
administered intravenously. Blood samples were obtained at 20 
and 40 min for the measurement of serum cortisol. Serum cortisol 
was measured using chemiluminescent enzyme immunoassay by 
our institution laboratory. Normal peak cortisol levels after stimu-
lation testing are >18 μg/dl. Serum ACTH was measured using a 
chemiluminescent immunoassay, and normal levels are 6–48 pg/
ml (Esoterix, Calabasas Hill, CA, USA).
statistics
We use descriptive statistics as well as median, mean, and range 
where appropriate. For patient demographics, all ages were cor-
rected for gestational age <40 weeks.
ethics
This study was approved by the Nationwide Children’s Hospital 
Institutional Review Board. Given the study design (a retrospec-
tive medical record review), a waiver of written or verbal consent 
was granted by the Institutional Review Board. The authors have 
no conflicts of interest related to this research.
resUlTs
During the study period, 59 patients with infantile spasms were 
referred to our Infantile Spasms Program. Of these, 45 patients 
received one or both hormone treatments. Two patients were 
excluded from the analysis – one due to congenital panhypopi-
tuitarism (including HPA insufficiency) and another because he 
received an alternative ACTH regimen at an outside institution. 
The 14 patients who did not receive hormone therapy were treated 
initially with vigabatrin and never received hormone therapy 
either due to remission with vigabatrin, a contraindication to 
hormone therapy, or death due to the underlying etiology of 
infantile spasms.
The median age of infantile spasms onset for those patients 
receiving hormone therapy was 6 months (mean 6, range 2–18). 
The median age of starting hormone therapy was 7 months (mean 
9, range 2–27). Eighteen of 42 (43%) received ACTH, 14/42 (33%) 
received prednisolone, and 10/42 (24%) patients received ACTH 
and prednisolone at some point during his/her treatment course 
(five received ACTH first and five received prednisolone first). 
Three patients receiving prednisolone had his/her dose increased 
from 40 to 60  mg/day during the course of treatment. In 5 of 
the 10 patients receiving both ACTH and prednisolone, the 
alternative hormone treatment was given after a hiatus between 
hormone therapies. In the other five patients, the alternative hor-
mone treatment was given immediately after the first hormone 
therapy; in four of these five cases, the initial hormone therapy 
was stopped early (due to ongoing infantile spasms), resulting 
in fewer total hormone treatment days (42, 43, 49, and 50 days, 
respectively).
Fourteen of 42 patients (33%) had a laboratory assessment of 
adrenal function following hormone treatment during the period 
in which this practice was part of our standardized management 
guideline. Eleven of 14 patients had adrenal stimulation testing: 
2 had glucagon stimulation testing and 9 had ACTH stimulation 
testing (Table 1). Patient 8 had adrenal stimulation testing fol-
lowing each hormone treatment (Table 1). The median interval 
between the last day of hormone therapy and the day of adrenal 
stimulation testing was 9  weeks (mean 14, range 2–18). In 11 
patients undergoing adrenal stimulation testing, comprising 
12 adrenal stimulation tests, 2/11 (18%) patients (Patient 6 and 
Patient 8) had suboptimal peak cortisol levels (Table 1). Detailed 
clinical data on these two patients are as follows.
Patient 6 had infantile spasms onset at 4 months of age and had 
a history of severe perinatal hypoxic ischemic encephalopathy. He 
received a full course of ACTH therapy starting at 6 months of 
age and had adrenal stimulation testing with glucagon 10 weeks 
after stopping ACTH. His baseline (obtained at 9:50 a.m.) cortisol 
(6.4 μg/dl) and ACTH levels (23 pg/ml) were normal. However, 
his peak cortisol with glucagon stimulation testing was subopti-
mal at 11.4 μg/dl (normal peak cortisol >18 μg/dl). He was then 
started on a physiological replacement hydrocortisone (10 mg/
m2/day) and received stress dose hydrocortisone for physical 
stress (febrile illness, trauma, or procedures). His hydrocortisone 
was slowly weaned off after being on hydrocortisone therapy for 
about 7 months. Repeat adrenal stimulation testing with ACTH 
1 month after weaning off hydrocortisone showed a normal peak 
cortisol level (19.5 μg/dl) indicating adequate adrenal function. 
This patient never displayed definitive clinical signs of adrenal 
insufficiency.
Patient 8 had infantile spasms onset at 6 months of age and 
had trisomy 21. He received a full course of prednisolone starting 
at 8 months of age. Three and a half weeks after stopping pred-
nisolone he had an undetectable (<0.9 μg/dl) random cortisol 
level (obtained at 2 p.m.). He was not started on maintenance 
hydrocortisone but adrenal stimulation testing was planned. 
Testing could not be performed until 4 weeks later (8 weeks after 
stopping prednisolone). At this time, his baseline (obtained at 
TaBle 1 | clinical and laboratory data of 11 patients who underwent adrenal stimulation testing.
Patient 
number
etiology corrected age at 
treatment initiation 
(months)
hormone 
treatmentd
Type of adrenal 
stimulation 
testing
interval: last 
hormone dose to 
test (weeks)
Baseline 
acTh level 
(nl: 6–48 pg/
ml)
Baseline cortisol 
levelf (time of 
day)
Peak 
cortisol (nl 
>18 μg/dl)
1 HIE 10 ACTH Glucagon 2 24 9.3 (1425) 19.9
2 PVL 6 ACTH ACTH 18 ND 10.4 (1405) 26.5
3 TBI 6 ACTH ACTH 2 27 8.6 (1440) 24.1
4 Unknownb 6 ACTH ACTH 10 ND 10.1 (0935) 33.1
5 Stroke 5 ACTH ACTH 8 39 15.4 (1415) 30.8
6 HIE 6 ACTH Glucagon 10 23 6.4 (1010) 11.4g
7 Unknownc 5 ACTH ACTH 13 25 11.6 (1022) 20.3
8a Trisomy 21 8 PREDe ACTH 8 7.4 3.1 (0908) 15.5g
12 ACTH ACTH 9 9.2 6.4 (1350) 23
9 IVH 8 ACTH ACTH 8 67 8.3 (1520) 24.5
10 Unknownb 19 PRED ACTH 6 ND 16.3 (1257) 35.2
11 HIE 5 PRED ACTH 15 27 20 (1000) 26
aPatient received 29 days each of PRED and ACTH (58 total treatment days).
bNormal neurological examination at infantile spasms onset.
cAbnormal neurological examination at infantile spasms onset.
dThe duration of treatment was 29 days for each drug.
eA random cortisol level 3.5 weeks after stopping PRED was undetectable (<0.9 μg/dl, 1400).
fNormal cortisol levels in children: 0800, 1–16 years old, range 3–21 μg/dl; 1600, 1/2 the 0800 value.
gTwo patients met laboratory criteria for adrenal insufficiency.
HIE, hypoxic ischemic encephalopathy; PVL, periventricular leukomalacia; TBI, traumatic brain injury; IVH, intraventricular hemorrhage; ACTH, adrenocorticotropic hormone; PRED, 
prednisolone; NL, normal; ND, not done.
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9 a.m.) cortisol (3.1 μg/dl) and ACTH (7.4  pg/ml) levels were 
normal. However, his peak cortisol level with ACTH stimulation 
testing was suboptimal at 15.5 μg/dl. Given his borderline peak 
cortisol level, he was prescribed hydrocortisone to be given only at 
the time of physical stress (febrile illness, trauma, or procedures). 
At 12 months of age, ACTH therapy was initiated for ongoing 
infantile spasms. Nine weeks after stopping ACTH therapy, 
adrenal stimulation testing with ACTH showed a normal peak 
cortisol level of 23 μg/dl. This patient never displayed definitive 
clinical signs of adrenal insufficiency.
Three patients had only random morning cortisol levels 
obtained following completion of hormone therapy. In two 
patients, the a.m. cortisol levels were 10 and 7.2 μg/dl at 10 and 
16 weeks after stopping hormone therapy, respectively. For these 
patients, no further endocrine testing was obtained given the 
absence of any clinical signs of adrenal insufficiency. The third 
patient was hospitalized for pneumonia and had an 8 a.m. cortisol 
level of 4.4 μg/dl. She was given stress dose hydrocortisone at 
50  mg/m2/day during the course of her febrile illness and was 
subsequently weaned off hydrocortisone within 3 weeks. Adrenal 
stimulation testing was planned for this patient but the family did 
not return for this scheduled test.
Due to the relatively low yield of a post-hormone therapy 
endocrinologist-guided laboratory evaluation in 14 patients, 
we chose to discontinue systematic laboratory monitoring and 
instead rely on clinical signs of adrenal insufficiency. Subsequently, 
one patient with an unknown etiology of infantile spasms, but 
abnormal development prior to infantile spasms onset, displayed 
clinical signs of mild adrenal insufficiency after receiving a full 
course of ACTH immediately followed by a full course of pred-
nisolone (maximum dose 40 mg/day) – a total of 2 months of 
hormone treatment. Increasing fatigue, decreased alertness, and 
poor feeding started 2 weeks after stopping prednisolone. She was 
treated with physiological replacement doses of hydrocortisone, 
resulting in clinical improvement. After 10  weeks of therapy, 
hydrocortisone was weaned off. However, she experienced recru-
descent signs of adrenal insufficiency almost immediately after 
stopping hydrocortisone. Hydrocortisone was restarted and was 
ongoing 4 months after stopping prednisolone (the time of last 
follow-up).
DiscUssiOn
This cases series includes 42 patients treated with hormone 
therapy for infantile spasms; 14 of these patients underwent an 
endocrinologist-guided laboratory assessment of adrenal func-
tion after hormone therapy. Eleven of 14 patients had adrenal 
stimulation testing and 2/11 (18%) patients had suboptimal peak 
cortisol levels. We contrast our study with three prior studies that 
have assessed adrenal function by stimulation testing after ACTH 
therapy in Table 2. In a study by Ross, 1/5 (20%) patients had 
abnormal adrenal stimulation testing (after the insulin tolerance 
test) soon after stopping natural ACTH (14). Perteentupa and 
colleagues reported two-thirds of their patients had abnormal 
adrenal stimulation testing (after combined vasopressin-synthetic 
ACTH) up to 2 weeks after stopping synthetic ACTH (13). Rao 
and Willis reported 5/9 (56%) patients with abnormal adrenal 
stimulation testing (after metyrapone infusion) 2 days after stop-
ping natural ACTH (15). The insulin tolerance test used by Ross, 
mimicking a severe stress, has been abandoned due to the risk of 
hypoglycemic seizures and severe hypokalemia after treatment 
with glucose infusion (19, 20). The metyrapone test used by Rao 
and Willis is an excellent test to evaluate the integrity of adrenal 
function, but it is rarely performed because of the difficulty in 
TaBle 2 | Four infantile spasms studies that report decreased pituitary or adrenal reserve with stimulation testing after hormone therapy.
study ross (14) Perheentupa et al. (13) rao and Willis (15) Mytinger and Bowden (22)
Number of patients 5 10 9c 11
Age of IS onset Unknown, but IS onset, 
diagnosed or treated: 
8 months to 8 years
Unknown, but admitted 
for treatment at a mean of 
9 months (range 5–22)
Unknown, but IS onset, 
diagnosed, or treated: median 
5.5 months (mean 7, range 
1.8–16)
Median 6 months (mean 8, 
range 5–19)
Treatment Natural ACTH Synthetic ACTH Natural ACTH Natural ACTH or prednisolone
Dose 1.1–9 IU/kg/day 80 IU (mean 9.5 IU/kg, range 
6.6–13.1)
20–40 IU/day (50–160 IU/m2/
day)d
150 IU/m2/day ACTH or 
40–60 mg/day PRED
Treatment duration range (days) 30–90 (“1–3 months”) 42 30–66 29
Type of testing Insulin infusion, then 
β-endorphin and serial 
cortisol levels
Combined vasopressin-
synthetic ACTH, then serial 
cortisol levels
Metyrapone infusion, then cortisol 
level
Synthetic ACTH or glucagon 
infusion, then serial cortisol 
levels
Timing of testing from last dose 
of hormone
Immediately after 
completion of ACTH
3 days, 1, and 2 weeks after 
completion of ACTH
2 days after completion of ACTH Median 9 weeks (mean 14, 
range 2–74) weeks after last 
hormone dose
↓ Hypothalamic–pituitary reserve 
or adrenal reserve
1a/5 3 days: 1b/6 5e/9 2f/11
1 week: 2b/4
2 weeks: 5b/8
Number with clinical AI Not discussed Not discussed Not discussed 1 (mild)
aPatient had normalization of hypothalamic–pituitary–adrenal axis function 6 weeks after abnormal testing.
bTesting was subnormal at 2 hour post ACTH.
cOne of 10 patients in the study did not have a post-treatment HPA axis assessment.
dNo taper was used.
eOnly one patient had subsequent adrenal stimulation testing, which was normal about 8 weeks after the last dose of ACTH.
fAdrenal stimulation testing was normal with the next evaluation 18.5 and 9 months after the last hormone dose in these two patients.
IS, infantile spasms; ACTH, adrenocorticotropic hormone; IU, international units; PRED, prednisolone; ↓, decreased; AI, adrenal insufficiency.
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obtaining metyrapone and the risk of precipitating an adrenal 
crisis (20). While the timing of HPA testing in all previous studies 
ranged from the next day to 2 weeks after ACTH withdrawal, our 
study assessed adrenal function at median interval of 9 weeks. 
The longer post-hormone adrenal function assessment adds to 
the limited literature on this topic. We found two patients with 
suppressed adrenal function 8 and 10  weeks after stopping 
natural ACTH and prednisolone, respectively. The length of 
HPA suppression in these two patients is similar to previous 
study in children with leukemia, reporting that a 4-week course 
of glucocorticoids resulted in suppression of the HPA axis for up 
to 8 weeks after discontinuation (21). While both patients in our 
study later had normal adrenal stimulation testing, our findings 
highlight the importance monitoring patients for signs of adrenal 
insufficiency after hormone therapy.
It is of interest that both patients with abnormal adrenal 
stimulation testing in our study had normal random cortisol and 
ACTH levels prior to abnormal adrenal stimulation testing. This 
suggests that random cortisol and ACTH levels are less sensitive 
to the detection of reduced adrenal reserve compared to adrenal 
stimulation testing. This can be explained by a study by Graber 
and colleagues who evaluated recovery of the HPA axis after 
withdrawal of chronic corticosteroid therapy (23). These authors 
demonstrated that ACTH was the first to normalize, followed by 
morning serum cortisol, and finally cortisol after adrenal stimu-
lation testing with ACTH. Therefore, at the time of the adrenal 
stimulation testing after hormone therapy, the serum ACTH 
and cortisol levels may have already normalized (depending on 
the timing of assessment). Under normal unstressed conditions, 
single ACTH concentration is not useful to detect secondary 
adrenal suppression (24).
Given the relatively low incidence of abnormal adrenal func-
tion testing after testing 14 patients, we removed the laboratory 
assessment of adrenal function from our standardized infantile 
spasms management guideline. Subsequently, one patient devel-
oped signs of mild adrenal insufficiency. While speculative, it is 
possible that the tandem use of the two hormone therapies pre-
disposed this patient to develop adrenal insufficiency. Although 
another patient treated with the two hormone therapies in tandem 
was proactively treated with stress dose hydrocortisone during a 
hospitalization for pneumonia, she was never formally diagnosed 
with adrenal insufficiency; this patient did not undergo adrenal 
stimulation testing, and she never required subsequent replace-
ment or stress dose hydrocortisone. Three other patients treated 
with both hormone therapies in tandem, and five patients treated 
with both hormone therapies with a hiatus between hormone 
therapies did not develop clinical signs of adrenal insufficiency. 
Based on a single patient with clinical adrenal insufficiency, it 
is not possible to delineate the risk of adrenal insufficiency in 
patients receiving one hormone therapy after another for the 
treatment of infantile spasms.
The post-hormone low-dose synthetic ACTH stimulation test 
utilized for most patients in our study is a sensitive and conveni-
ent test for secondary adrenal insufficiency, although caution is 
advised for possible false negative results in patients with recent 
or mild secondary adrenal insufficiency, as the adrenal glands 
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may respond normally to exogenous ACTH. Glucagon stimula-
tion testing is a sensitive test for evaluating adrenal function and 
is not associated with the risks of insulin-induced hypoglycemia. 
Glucagon administration causes an increase in blood glucose, 
which then evokes an endogenous insulin response, resulting 
in a fall in blood glucose that stimulates a counter-regulatory 
hormone response that includes cortisol (25).
Limitations of our study include our retrospective study design, 
an overall small sample size with a limited number of patients 
undergoing a post-hormone laboratory assessment of adrenal 
function, and differing preferences among endocrinologists in 
the type of adrenal function testing utilized. Despite these limita-
tions, our study adds to this limited body of literature and is the 
only study to assess adrenal function following consistently uti-
lized modern hormone treatment regimens for infantile spasms. 
Given the potential risk of life-threatening adrenal crisis (20), we 
recommend that clinicians should be vigilant in monitoring for 
signs of adrenal insufficiency for at least 3  months (or longer) 
after withdrawal of hormone therapy. Ideally, dynamic adrenal 
function testing, with ACTH stimulation testing or glucagon 
stimulation testing, would be obtained in all patients. However, 
this may not be feasible in routine practice. Alternatively, pro-
phylactic coverage with stress dose hydrocortisone should be 
given in times of physical stress (e.g., febrile illness, trauma, or 
procedures), as suggested by Chamberlin and colleagues (10). 
It is critical that caregivers should be educated on the signs of 
adrenal insufficiency. Further studies are needed to evaluate the 
effectiveness of this approach in prevention of morbidity associ-
ated with HPA suppression in infantile spasms patients treated 
with hormone therapy.
summary and conclusion
Our study suggests that adrenal suppression can occur after 
treatment of modern hormone therapy regimens. Although we 
found relatively few patients with abnormal adrenal stimulation 
testing (18%) and only one additional patient with clinical signs 
adrenal insufficiency, given the seriousness of adrenal crisis, we 
recommend caregiver education on the signs of adrenal insuf-
ficiency. Greater vigilance may be indicated in those patients 
receiving the both types of hormone therapy in tandem. A routine 
post-hormone endocrinologist-guided laboratory assessment of 
adrenal function may not be feasible in all patients. We recom-
mend prophylactic hydrocortisone when there is any concern for 
adrenal insufficiency, especially in times of stress. Further studies 
are needed to confirm the timing of a full recovery of the HPA axis 
in patients with infantile spasms treated with hormone therapy.
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